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Summary Depletion of skeletal muscle mass in animals bearing an experimental model of cachexia, the
MAC16 adenocarcinoma, occurs by a reduction in protein synthesis accompanied by a large increase in
protein degradation. Serum from mice bearing the MAC16 tumour produced an increased protein degradation
in isolated gastrocnemius muscle, as measured by tyrosine release, with a maximal effect occurring with serum
from animals with a weight loss of between and 20%. The response was specific to the cachectic state, since
serum from mice bearing the MAC13 adenocarcinoma, which does not produce weight loss, did not increase
tyrosine release from gastrocnemius muscle above that observed with serum from non tumour-bearing
animals. The circulatory proteolysis-inducing factor was stable to heating at 60°C for 5 min and was not
inhibited by phenylmethylsulfonyl fluoride, suggesting that it was not a serine protease. The level of
prostaglandin E2 (PGE2) in gastrocnemius muscle was significantly elevated after incubation with serum from
cachectic mice bearing the MAC16 tumour. Both indomethacin and the polyunsaturated fatty acid eicosapen-
taenoic acid (EPA) inhibited the rise in muscle PGE2 content in response to serum from cachectic mice and
also inhibited muscle protein degradation. These results suggest that muscle protein degradation in cancer
cachexia is associated with a rise in PGE2 content.
Muscle wasting associated with cancer cachexia is an impor-
tant complication in the management of the cancer patient
and can lead to death through a depletion of cardiac and
respiratory muscles. Maintenance of skeletal muscle mass is a
balance between the rate of protein synthesis and the rate of
protein degradation, and in mice bearing an experimental
model of cachexia, the MAC16 colon adenocarcinoma, pro-
tein synthesis is reduced and protein degradation is increased
with increasing weight loss (Beck et al., 1991). This model is
particularly attractive for studying changes in protein balance
with the development of cachexia, since weight loss occurs
without a reduction in food intake and reaches 30% when
the tumour mass only represents 3% of the host body weight
(Beck & Tisdale, 1987).
The relevance of protein degradation to the overall
aietology of the tumour remains unknown, although an in-
creased requirement for certain amino acids particularly
leucine (Lazo, 1981) and glutamine (Kallinowski et al., 1987)
has been observed in the tumour-bearing state. Stein (1978)
has attributed the abnormal gluconeogenesis seen in cancer
patients to the avidity of the tumour for certain amino acids,
which left the host with the problem of disposing of the
remainder. Removal of certain amino acids by the tumour
would lead to a depression of host protein synthesis since
normal protein synthesis requires the full complement of
amino acids.
The mechanism for the increased protein degradation in
cancer cachexia remains unknown, although we have noted
increased levels of a proteolysis-inducing factor in the serum
of mice bearing the MAC16 adenocarcinoma (Beck & Tis-
dale, 1987). Such circulating factors may act to increase the
level of lysosomal enzymes, such as cathepsin D, which may
be involved in the intracellular breakdown of mac-
romolecules. Thus Lundholm et al. (1978) have demonstrated
an increased concentration of cathepsin D in skeletal muscle
tissue from cancer patients and tumour-bearing mice.
The present study further investigates the mechanism for
protein degradation in gastrocnemius muscle of mice bearing
the MAC16 tumour with particular reference to the serum
factor previously reported (Beck & Tisdale, 1987). In addi-
tion the effect of inhibitors on this process have been deter-
mined.
Materials and methods
Animals
Pure strain female NMRI mice were obtained from our own
breeding colony and were fed a rat and mouse breeding diet
(Pilsbury Ltd., Birmingham, UK) and water ad libitum.
Animals (average body weight 20 g) were transplanted with
fragments of the MAC16 tumour into the flank by means of
a trocar as previously described (Bibby et al., 1987). Weight
loss started to occur 10 to 12 days after transplantation when
the tumours became palpable and animals were used with
varying degrees of weight loss up to a maximum of 25 to
30% as agreed by the Coordinating Committee on Cancer
Research of the United Kingdom for the welfare of animals
with neoplasms. Blood was removed from animals by cardiac
puncture under anesthesia using a mixture of halothane,
oxygen and nitrous oxide between 9.30 and 10.30a.m. Blood
samples were allowed to clot for 10 min at room temperature
and serum was produced by centrifugation at 13,000 rpm for
5 min an a microfuge. Serum samples were stored at - 70°C
until required.
Chemicals
Indomethacin, prostaglandin E2 (PGE2), rabbit antisera to
PGE2 were purchased from Sigma Chemical Co., Poole,
Dorset, United Kingdom. Eicosapentaenoic acid (EPA)
(80%, expressed as a percentage of fatty acid methyl esters
prepared) was kindly donated by Dr D. Horrobin, Scotia
Pharmaceuticals Ltd., Guildford, Surrey, United Kingdom.
BW A4C was kindly supplied by Dr L.G. Garland, Well-
come Research Laboratories, Beckenham, Kent, United
Kingdom.
Measurement ofprotein degradation
Female NMRI mice were killed by cervical dislocation and
their gastrocnemius muscles were quickly ligated, dissected
out and placed in ice-cold isotonic saline. For the experiment
presented in Figure 6 animals were administered pure EPA
(2 g per kg per day) orally for 5 days prior to the isolation of
the gastrocnemius muscle. All animals were sacrificed
between 9-10a.m. to minimise diurnal variation and were
assured to be in the fed state. The muscles were then blotted,
weighed and carefully tied via tendon ligatures (Wu &
Thompson, 1988) to stainless steel incubation supports to
prevent contraction, thus improving protein balance and
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energy status (Baracos & Goldberg, 1986). Protein degrada-
tion was measured by tyrosine release, since tyrosine rapidly
equilibrates between intracellular pools and the medium and
it is neither synthesised nor degraded. Muscles were prein-
cubated in Dulbecco's minimal essential medium (DMEM)
(3 ml) lacking phenol red and saturated with 02:C02 (19:1)
in the presence of serum (280 1il). After 30 min at 37°C the
muscles were rinsed and incubated in Krebs-Henseleit bicar-
bonate buffer for a further 2 h. After the final 2 h incubation
the buffer was removed, deproteinised with ice-cold 30%
trichloroacetic acid (0.2 ml), centrifuged at 2800 g for Omin
and the supernatants were used for the measurement of
tyrosine by a fluorimetric method (Waalkes & Undenfriend,
1957) at 570 nm on a Perkin-Elmer LS-5 luminescene spect-
rometer.
Determination ofPGE2 levels in muscle samples
Slices of gastrocnemius muscle were incubated in Krebs-
Ringer bicarbonate buffer (2 ml) supplemented with glucose
(1 mg ml-') and bovine serum albumin (I mg ml-') in a
shaking water bath at 37C. Muscle preparations were
incubated initially for 20 min under an atmosphere of 5%
(CO2, 95% N2 and then for a further 15 min under an
atmosphere of 5% CO2, 95% 02. At the end of the incuba-
tion period an aliquot (1 ml) of the surrounding buffer was
removed, adjusted to pH 3 with 2 M HCI and extracted twice
with ethyl acetate saturated with water (3 ml). The organic
layer was removed, evaporated to dryness under a stream of
nitrogen and dissolved in 1 ml of 0.025 M phosphate, pH 6.8,
containing 0.01 M EDTA, 0.9% NaCl, 0.3% bovine gamma
globulin, 0.005% triton X-100 and 0.05% sodium azide. The
concentration of PGE2 in the sample was determined using a
radioimmunoassay procedure employing rabbit anti-PGE2
antisera. [5,6,8,1 1,12,14,15(N)-3H] Prostaglandin E2 (specific
activity 150 Ci mmol-') (Amersham International, Amer-
sham, UK) was diluted to give a concentration of 4.26 nCi/
assay. Bound and unbound material was separated using
dextran coated charcoal and separated by centrifugation.
Results
We have previously shown that loss of skeletal muscle pro-
tein in mice bearing the MAC16 adenocarcinoma arises from
a depression of protein synthesis accompanied by a massive
increase in protein degradation, which increases with increas-
ing weight loss (Beck et al., 1991). Using the isolated gast-
rocnemius muscle model an increased protein degradation as
measured by tyrosine release, can be produced by incubation
with serum from mice bearing the MAC16 tumour (Figure
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Figure 1 Effect of serum from mice bearing the MAC 16 tumour
and with progressive weight loss on tyrosine release from gast-
rocnemius muscle. Serum (280 il i.e. 7% of assay volume) was
added to freshly isolated gastrocnemius muscle isolated from non
tumour-bearing animals and the tyrosine released during a 2 h
incubation was determined as described in Methods. Each bar
represents the mean ± s.e.m. of four animals. Differences were
determined by one-way analysis of variance as *P <0.05 and
**P<0.01 from non tumour-bearing animals.
1). Increasing weight loss produces an increased degradation
activity up to a weight loss of 20%, after which the level
decreases to a value not significantly different from that
found in animals without weight loss.
This effect appears to be specific to serum from cachectic
animals since serum from mice bearing a closely related
tumour, MAC13, which does not induce cachexia, did not
increase tyrosine release from gastrocnemius muscle above
that observed with non tumour-bearing animals (Figure 2).
The proteolysis-inducing factor in the serum from animals
bearing the MAC16 tumour is stable to heating at 60°C for
5 min (Figure 2) and is not inhibited by 1 mM phenylmethyl-
sulfonyl fluoride, suggesting that it is not a serine protease.
Inhibition could, however, be achieved by the addition of the
cycloxoygenase inhibitor indomethacin (0.2 mM). There was a
decrease by both the polyunsaturated fatty acid EPA
(0.5 mM) and the lipoxygenase inhibitor BWA4C (Tateson et
al., 1988) at high concentrations (1.77 mM) although the
values were still significantly elevated compared to the cont-
rol. Protein degradation in isolated gastrocnemius muscle
could not be induced by the purified lipid mobilising factor
produced by the MAC16 tumour (Beck et al., 1990). These
results suggest that serum from cachectic animals bearing the
MAC16 tumour acts to initiate protein degradation in
skeletal muscle through the intermediacy of a prostaglandin
intermediate.
This view is substantiated by the significant elevation in
gastrocnemius muscle PGE2 content after incubation with
serum from cachectic mice bearing the MAC16 tumour,
when compared with that observed with serum from non
tumour-bearing animals (Figure 3). The effect appeared to
arise from a stimulation of PGE2 production by the gast-
rocnemius muscle, since the PGE2 concentration of serum
from cachectic animals bearing the MAC16 tumour
(111 pg ml-') was lower than that found in non tumour-
bearing animals (147 pg ml-'). Indomethacin reduced both
tyrosine release from gastrocnemius muscle in response to
serum from cachectic animals and the subsequent elevation in
PGE2 content in a dose-related manner (Figure 4). A large
(66%) reduction in muscle PGE2 content was required before
a significant reduction in muscle proteolysis was observed.
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Figure 2 Effect of serum from non tumour-bearing animals (1),
animals bearing the MAC13 tumour (2), the MAC16 tumour
from mice with II -16% weight loss (3 -8) or a partially purified
lipid mobilising factor (9) on tyrosine release from isolated gas-
trocnemius muscle. Serum from animals bearing the MAC16
tumour was used as such (3), heated to 60°C for 5 min (4), treated
with phenylmethylsulfonyl fluoride (1 mM) (5), indomethacin
(0.2 mM) (6), EPA (0.5 mM) (7) or BWA4C (1.77 mM) (8). Each
bar represents the mean ± s.e.m. of three animals. Differences
were determined by one-way analysis of variance as P <0.05 and
*P<0.01 compared to group 1.
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Figure 3 Effect of serum from non tumour-bearing animals
(closed box) and animals bearing the MACl6 tumour and with
weight loss 11-15% (hatched box) on the PGE2 content of
isolated gastrocnemius muscle. Each bar represents the
mean ± s.e.m. of six animals. Differences were determined by
Student's t-test as "'P<0.001 from muscles treated with serum
from non tumour-bearing animals.
We have recently reported that eicosapentaenoic acid
(EPA) is an effective inhibitor of the weight loss in animals
bearing MAC16 tumour (Beck et al., 1991). Maintenance of
skeletal muscle mass by EPA in animals bearing the MAC16
tumour was found to arise from a significant reduction
(60%) in muscle protein degradation without an effect on
protein synthesis. The inhibitory effect of EPA on muscle
protein degradation may result from its ability to inhibit
PGE2 synthesis. The results presented in Figure 5 show that
addition of EPA directly to the in vitro gastrocnemius muscle
preparation caused a dose-related reduction in both tyrosine
release and PGE2 production in response to serum from
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Figure 5 Effect of EPA on the PGE2 content (hatched box) and
tyrosine release (closed box) from isolated gastrocnemius muscle
in response to serum from animals bearing the MAC16 tumour
and with weight loss 11-15%. Each bar represents the
mean ± s.e.m. of three animals. Differences were determined by
one-way analysis of vaniance as *P<0.05 and "*P<0.01 com-
pared to no addition of EPA.
cachectic animals. However, high concentrations (500gLM) of
EPA were required to produce a significant reduction in
muscle PGE2 content and tyrosine release.
The low effectiveness of EPA in this in vitro assay may be
due to poor incorporation of the fatty acid into muscle lipids,
since pre-treatment of animals with EPA (2 gkg-') for 5
days prior to the assay was much more effective in inhibiting
both tyrosine release and the PGE2 content of the isolated
gastrocnemius muscle in response to serum from cachectic
mice bearing the MAC16 tumour (Figure 6). Using muscles
from animals snot pre-treated with EPA there was a
significant (P<0.01) increase in tyrosine release and PGE2
content in response to serum from cachectic mice when
compared with that observed with non tumour-bearing
animals. However, in gastrocnemius muscle isolated from
non tumour-bearing animals previously pre-treated with
EPA, there was a significant reduction (P<0.001) in both
protein degradation, as measured by tyrosine release and
PGE2 content. This confirms that the pre-treatment of the
donor muscle with EPA reduces protein degradation to levels
seen in muscles produced by serum from non tumour-bearing
animals. These results suggest that the maintenance of
skeletal muscle mass by EPA in cachectic animals bearing the
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Figure 4 Effect of indomethacin on tyrosine release from
isolated gastrocnemius muscle (closed boxes) and PGE2 content
(hatched boxes) after a 2 h incubation. Results are expressed as
mean ± s.e.m. for 12 determinations per group. Differences were
determined by one-way analysis of variance as 'P<0.05 and
"P<0.01 compared to muscles incubated in the absence of
indomethacin.
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Figure 6 Effect of treatment ofmice with EPA (2.0 g kg day) for
5 days by gavage on the response of isolated gastrocnemius
muscle to induction of protein degradation as measured by
tyrosine release (solid boxes) and muscle PGE2 content (hatched
boxes) in response to serum (280Il) from cachectic animals
bearing the MAC16 tumour (weight loss 10-15%). Differences
were determined by Student's t-test as "'.P<0.001 from animals
not pre-treated with EPA.
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MAC16 tumour arises from the ability to inhibit PGE2 for-
mation.
Discussion
We have previously shown (Beck et al., 1991) that wasting of
gastrocnemius muscle in cachectic animals bearing the
MAC16 tumour is associated with a decrease in protein
synthesis combined with a large increase in protein degrada-
tion as the weight loss increases. This model is particularly
useful for such studies since caloric intake does not decrease
with increasing loss of skeletal muscle mass (Beck & Tisdale,
1987). Previous studies have shown that serum of cancer
patients with weight loss greater than 10% also contains a
proteolysis-inducing factor (Belizario et al., 1991) similar to
that reported in the present study. The material described in
the present study appears to be specific for the cachectic
state, since sera from mice bearing the MAC13 tumour,
which is of a similar histological type to the MAC16 tumour,
but does not induce cachexia, did not increase protein deg-
radation in isolated gastrocnemius muscle above that found
with sera from non tumour-bearing animals. The level of the
proteolysis-inducing factor in the serum of mice bearing the
MAC16 tumour increases with increasing weight loss up to
20%. We have previously noted a similar rise and then fall of
a lipid mobilising factor in the serum of both cancer patients
and in mice bearing the MAC16 tumour (Groundwater et al.,
1990). In both cases the maximum level appeared to be
reached when the weight loss was between 16 and 20%. This
correlates with the rate ofweight loss which increases linearly
for animals with a weight loss between 9 and 20% up to a
maximum of 1.8 g per day and thereafter decreases to a value
of only 0.3 g per day when the weight loss reaches 28%
(Groundwater et al., 1990).
The circulating proteolysis-inducing factor appears to
initiate protein degradation in gastrocnemius muscle by in-
creasing the PGE2 content. Some studies suggest that the
cytokine tumour necrosis factor alpha (TNF-a) (Flores et al.,
1989) alone, or in combination with interleukin-I (IL-l)
(Hellerstein et al., 1989) increase muscle proteolysis through
a prostaglandin intermediate. A proteolysis-inducing factor
has been shown to be present in the plasma proteins of 25
out of 50 cancer patients with weight loss and in five of these
samples the bioactivity was partially abrogated with
antibodies to recombinant IL-1 (Belizario et al., 1991). Thus
the accelerated breakdown of protein appeared to be
mediated by IL-1 in co-operation with other unidentified
factors. However, Moldawer et al. (1987) have shown that
neither TNF-a or IL-1 regulate protein balance in skeletal
muscle in vitro. Also in the present study the serum
proteolysis-inducing factor is stable to heating at 60°C for
5 min suggesting that it is not a cytokine. Thus the role of
cytokines in this process must remain somewhat controver-
sial.
In vitro experiments suggest that prostaglandin production
may be involved in the regulation of protein synthesis and
degradation in various types of striated muscle. Rates of
protein degradation have been shown to be increased by
arachidonate and the most important metabolite appears to
be PGE2, while PGF2, caused a stimulation of protein syn-
thesis without affecting degradation (Rodeman & Goldberg,
1982). PGE2 possibly stimulates protein degradation through
the activation of intralysosomal proteolysis. Since
preliminary experiments suggest that the serum level of
arachidonate is increased with increasing weight loss in
animals bearing the MAC16 tumour, mobilisation of fatty
acids from adipose tissue may be responsible for proteolysis
of skeletal muscle in cancer cachexia.
Indomethacin, an inhibitor of the cyclo-oxygenase, was
capable of inhibiting proteolysis in isolated gastrocnemius
muscle in response to' serum from animals bearing the
MAC16 tumour with weight loss. The inhibition of pro-
teolysis by indomethacin seemed to correlate with the inhibi-
tion of PGE2 production. Treatment of rats bearing the
Yoshida ascites hepatoma AH130 with another cyclo-oxy-
genase inhibitor, naproxen, inhibited PGE2 production and
muscle protein loss, but had no effect on muscle protein
degradation in rats bearing Morris hepatoma 7777, which
appeared to induce cachexia in a prostaglandin-independent
manner (Strelkov et al., 1989). Thus other factors in addition
to prostaglandins may also be involved.
The inhibitory effect of EPA on muscle protein degrada-
tion in animals bearing the MAC16 tumour also appears to
arise from an inhibition of PGE2 production. Incorporation
of EPA into muscle phospholipids leads to competition with
arachidonate for the cyclooxygenase in response to phos-
pholipase A2 (Levine & Worth, 1984). Thus EPA seems
ideally suited to the treatment of cancer cachexia, since in
addition to its effect on muscle protein degradation, it is also
an effective inhibitor of tumour-induced lipid mobilisation
(Tisdale & Beck, 1991).
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